ArticleACS synthetic biology2025
Reprogramming the SARS-CoV-1 Neutralizing Antibody S230 to SARS-CoV-2 via Directed Evolution and Molecular Docking-Based Binding Mode Analysis.
Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a ferritin-based subunit nanoparticle vaccine targeting the S-RBD of porcine transmissible gastroenteritis virus.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To reprogram the antigen specificity of the SARS-CoV-1 neutralizing antibody S230 toward SARS-CoV-2, we employed a strategy combining directed evolution with molecular docking-based analysis. An error-prone scFv library was constructed from S230 and screened via bacterial display using the SARS-CoV-2 RBD. Among the enriched clones, IJ36 regained SARS-CoV-2 RBD binding and was further refined to an optimized variant, IJ36-V. IJ36-V efficiently neutralized SARS-CoV-2 infection and retained cross-reactivity with the SARS-CoV-1 RBD, confirming that the reprogrammed antibody preserved the ancestral specificity while extending its functional breadth. Docking simulations revealed that two substitutions, R56W and N57Y, function cooperatively to stabilize the binding interface through favorable hydrogen bonding and aromatic interactions. Reversion analysis confirmed that both mutations are essential for high-affinity binding, with neither being sufficient alone. These findings demonstrate that a limited set of synergistic mutations can reconstitute antigen recognition between evolutionarily divergent but structurally conserved targets. This study establishes a modular and evolvable platform for antibody reprogramming based on synthetic biology principles, enabling rapid adaptation of existing scaffolds to emerging pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.